These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17485151)

  • 21. Serological study in Tunisian cervical cancer patients.
    Achour M; Kochbati L; Zeghal D; Kahla S; Maalej M; Zouari F; Oueslati R
    Pathol Biol (Paris); 2009 Jul; 57(5):415-9. PubMed ID: 18586408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
    Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
    Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
    Villa LL; Ault KA; Giuliano AR; Costa RL; Petta CA; Andrade RP; Brown DR; Ferenczy A; Harper DM; Koutsky LA; Kurman RJ; Lehtinen M; Malm C; Olsson SE; Ronnett BM; Skjeldestad FE; Steinwall M; Stoler MH; Wheeler CM; Taddeo FJ; Yu J; Lupinacci L; Railkar R; Marchese R; Esser MT; Bryan J; Jansen KU; Sings HL; Tamms GM; Saah AJ; Barr E
    Vaccine; 2006 Jul; 24(27-28):5571-83. PubMed ID: 16753240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies.
    Xie X; Liu Y; Zhang T; Xu Y; Bao Q; Chen X; Liu H; Xu X
    Arch Virol; 2013 Jan; 158(1):193-9. PubMed ID: 22965579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly.
    Kuck D; Leder C; Kern A; Müller M; Piuko K; Gissmann L; Kleinschmidt JA
    Vaccine; 2006 Apr; 24(15):2952-65. PubMed ID: 16414157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
    Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
    Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.
    Kirnbauer R; Chandrachud LM; O'Neil BW; Wagner ER; Grindlay GJ; Armstrong A; McGarvie GM; Schiller JT; Lowy DR; Campo MS
    Virology; 1996 May; 219(1):37-44. PubMed ID: 8623552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
    Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M
    Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.
    Bolhassani A; Shirbaghaee Z; Agi E; Davoudi N
    Protein Expr Purif; 2015 Dec; 116():7-11. PubMed ID: 26304732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
    Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.
    Kwak K; Jiang R; Jagu S; Wang JW; Wang C; Christensen ND; Roden RB
    PLoS One; 2013; 8(3):e60507. PubMed ID: 23536912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
    Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
    Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.
    Liu DW; Chang JL; Tsao YP; Huang CW; Kuo SW; Chen SL
    Int J Cancer; 2005 Jan; 113(1):93-100. PubMed ID: 15386434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization with Human Papillomavirus 16 L1+E2 Chimeric Capsomers Elicits Cellular Immune Response and Antitumor Activity in a Mouse Model.
    López-Toledo G; Schädlich L; Alonso-Castro ÁJ; Monroy-García A; García-Rocha R; Guido MC; Gissmann L; García-Carrancá A
    Viral Immunol; 2016 Jun; 29(5):276-87. PubMed ID: 27058179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.
    Jagu S; Kwak K; Garcea RL; Roden RB
    Vaccine; 2010 Jun; 28(28):4478-86. PubMed ID: 20434552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.
    Evans TG; Bonnez W; Rose RC; Koenig S; Demeter L; Suzich JA; O'Brien D; Campbell M; White WI; Balsley J; Reichman RC
    J Infect Dis; 2001 May; 183(10):1485-93. PubMed ID: 11319684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prokaryotic expression and purification of human papillomavirus type 11 L2E7 fusion protein vaccine and its immunnogenicity].
    Zhang H; Zhao L; Ren J; Gao J; Bian T; Fan JT; Ruan L; Chen XQ; Tian HW
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):156-8. PubMed ID: 17653322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.